Teal Vinger
Family · Fairbanks, AKNPI 1578148284
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 255 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Novo Nordisk at 27.5% of the total. Among family clinicians in AK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 255 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$1K
- AstraZeneca$986
- Lilly USA, LLC$406
- Pfizer$223
- Biohaven Pharmaceutical Holding Company Ltd.$218
- plus $640 from 18 others
What the payments were for
- Food & beverage$5,39299%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 90 | $1,492 |
| AbbVie | 49 | $1,460 |
| AstraZeneca | 49 | $986 |
| Lilly USA, LLC | 17 | $406 |
| Pfizer | 12 | $223 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $218 |
| GSK | 5 | $108 |
| Rhythm Pharmaceuticals, Inc. | 3 | $79 |
| Otsuka America Pharmaceutical, Inc. | 2 | $53 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $48 |
| Merck | 3 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Alkermes, Inc. | 2 | $39 |
| Clarus Therapeutics Inc. | 2 | $34 |
| Antares Pharma, Inc. | 1 | $25 |
| Vivus LLC | 1 | $24 |
| Exact Sciences | 1 | $23 |
| IBSA Pharma Inc. | 1 | $21 |
| Halozyme Inc | 1 | $19 |
| TMS Neurohealth Centers Inc. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$379
- UBRELVY$253
- NURTEC ODT$125
- Wegovy$125
How this compares
$5,424 in reported general payments places this provider in the 95th percentile of 315 family providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 14 | $1,130 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $403 |
| Rosuvastatin Calcium | 11 | $222 |
| Losartan Potassium | 14 | $182 |
| Atorvastatin Calcium | 12 | $173 |
| Levothyroxine Sodium | 11 | $98 |
| Amlodipine Besylate | 15 | $93 |
| Tizanidine Hcl | 11 | $37 |
Paid to pharmacies, not to this prescriber.
Other family in Fairbanks
- Kristy BloodFairbanks$7K
- Casey BloodFairbanks$7K
- Brianna GrahamFairbanks$4K
- Joan DigeorgeFairbanks$3K
- Robert RosentreterFairbanks$2K
- Karolina PriebeFairbanks$2K
- Ruth RosentreterFairbanks$1K
- Erica HeagyAnchorage$249K
- Trisha KernodleAnchorage$60K
- Whitney CarlsonSoldotna$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.